The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors (AEJ:AE 2012)

From ReplicationWiki
Jump to: navigation, search
How revelant do you consider a replication of this study? You may discuss on the discussion page.


Nobody voted on this yet

 You need to enable JavaScript to vote


Here you find a ranking of the studies that are regarded most relevant to be replicated.

Contents

Article

Authors Title Journal Year Edition Pages JEL Codes Keywords
Craig L. Garthwaite The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors AEJ:AE 2012 3 116- 137 I12, J22, L65, O31 -

Article information

Program code Data Readme Method(s) & estimation Data type Data used Origin of data used Software used (Version)
1 - accessible on journal website 1 - accessible on journal website 1 - accessible on journal website Fixed effects (FE), Difference in differences (DID), Clustering, Instrumental variable (IV) Micro Medical Expenditure Panel Survey, apparently not available for tables 1, 2, and 5 USA Stata

Replication of this study

Authors Title Journal Year Edition Pages JEL Codes Keywords Replication type Replication result [refer to replication type 1 and 2] Raw data Call into question Authors statement

References

DOI: 10.1257/app.4.3.116 IDEAS: a/aea/aejapp/v4y2012i3p116-37.html EconPapers: RePEc:aea:aejapp:v:4:y:2012:i:3:p:116-37


Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox